Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer.

Y. J. Nam, Chul Won Choi, Sang Won Shin, Kwang Ho In, Kyung Ho Kang, Jun Suk Kim, Young Ho Choi, Chul Yong Kim, M. S. Choi

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Small cell lung cancer is sensitive to chemotherapy and radiotherapy. Nevertheless, responses are still short-lived and apparent cure remains for only limited disease patients. METHODS: We combined cyclophosphamide (750 mg/m2 by intravenous infusion at first day) vincristine (2 mg intravenously at third day), cisplatin (20 mg/m2 intravenously for 3 days), and etoposide (100 mg/m2 intravenously for 3 days) with radiotherapy (total 300cGy over 4 weeks in 17 fractions) and treated 39 patients with small cell lung cancer who had received no prior systemic chemotherapy and radiotherapy. RESULTS: 1) Thirty-nine patients (limited disease: 17 patients, extensive disease 22 patients) were treated and 35 patients were evaluable for response. Overall response rate was 82.8% (complete response 28.6%, partial response 54.2%). 2) The median survival was 52 weeks for all patients and 58 weeks for limited disease and 45 weeks for extensive disease. There was no statically significant survival difference between the two patient groups. The median relapse-free survival time was 48 weeks. 3) Overall, treatment was well tolerated, with granulocytopenia being the most frequent toxicity. CONCLUSIONS: Combination chemotherapy with COPE regimen combined with radiation therapy was effective as a first line therapy for SCLC.

Original languageEnglish
Pages (from-to)32-37
Number of pages6
JournalKorean Journal of Internal Medicine
Volume10
Issue number1
Publication statusPublished - 1995 Jan 1

Fingerprint

Small Cell Lung Carcinoma
Vincristine
Etoposide
Combination Drug Therapy
Cyclophosphamide
Cisplatin
Radiotherapy
Survival
Drug Therapy
Agranulocytosis
N-succinyl-1,2-dioleoylphosphatidylethanolamine
Intravenous Infusions
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{538a6f2455a74ab884070af2bdbeb727,
title = "Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer.",
abstract = "OBJECTIVES: Small cell lung cancer is sensitive to chemotherapy and radiotherapy. Nevertheless, responses are still short-lived and apparent cure remains for only limited disease patients. METHODS: We combined cyclophosphamide (750 mg/m2 by intravenous infusion at first day) vincristine (2 mg intravenously at third day), cisplatin (20 mg/m2 intravenously for 3 days), and etoposide (100 mg/m2 intravenously for 3 days) with radiotherapy (total 300cGy over 4 weeks in 17 fractions) and treated 39 patients with small cell lung cancer who had received no prior systemic chemotherapy and radiotherapy. RESULTS: 1) Thirty-nine patients (limited disease: 17 patients, extensive disease 22 patients) were treated and 35 patients were evaluable for response. Overall response rate was 82.8{\%} (complete response 28.6{\%}, partial response 54.2{\%}). 2) The median survival was 52 weeks for all patients and 58 weeks for limited disease and 45 weeks for extensive disease. There was no statically significant survival difference between the two patient groups. The median relapse-free survival time was 48 weeks. 3) Overall, treatment was well tolerated, with granulocytopenia being the most frequent toxicity. CONCLUSIONS: Combination chemotherapy with COPE regimen combined with radiation therapy was effective as a first line therapy for SCLC.",
author = "Nam, {Y. J.} and Choi, {Chul Won} and Shin, {Sang Won} and In, {Kwang Ho} and Kang, {Kyung Ho} and Kim, {Jun Suk} and Choi, {Young Ho} and Kim, {Chul Yong} and Choi, {M. S.}",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "10",
pages = "32--37",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "1",

}

TY - JOUR

T1 - Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer.

AU - Nam, Y. J.

AU - Choi, Chul Won

AU - Shin, Sang Won

AU - In, Kwang Ho

AU - Kang, Kyung Ho

AU - Kim, Jun Suk

AU - Choi, Young Ho

AU - Kim, Chul Yong

AU - Choi, M. S.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - OBJECTIVES: Small cell lung cancer is sensitive to chemotherapy and radiotherapy. Nevertheless, responses are still short-lived and apparent cure remains for only limited disease patients. METHODS: We combined cyclophosphamide (750 mg/m2 by intravenous infusion at first day) vincristine (2 mg intravenously at third day), cisplatin (20 mg/m2 intravenously for 3 days), and etoposide (100 mg/m2 intravenously for 3 days) with radiotherapy (total 300cGy over 4 weeks in 17 fractions) and treated 39 patients with small cell lung cancer who had received no prior systemic chemotherapy and radiotherapy. RESULTS: 1) Thirty-nine patients (limited disease: 17 patients, extensive disease 22 patients) were treated and 35 patients were evaluable for response. Overall response rate was 82.8% (complete response 28.6%, partial response 54.2%). 2) The median survival was 52 weeks for all patients and 58 weeks for limited disease and 45 weeks for extensive disease. There was no statically significant survival difference between the two patient groups. The median relapse-free survival time was 48 weeks. 3) Overall, treatment was well tolerated, with granulocytopenia being the most frequent toxicity. CONCLUSIONS: Combination chemotherapy with COPE regimen combined with radiation therapy was effective as a first line therapy for SCLC.

AB - OBJECTIVES: Small cell lung cancer is sensitive to chemotherapy and radiotherapy. Nevertheless, responses are still short-lived and apparent cure remains for only limited disease patients. METHODS: We combined cyclophosphamide (750 mg/m2 by intravenous infusion at first day) vincristine (2 mg intravenously at third day), cisplatin (20 mg/m2 intravenously for 3 days), and etoposide (100 mg/m2 intravenously for 3 days) with radiotherapy (total 300cGy over 4 weeks in 17 fractions) and treated 39 patients with small cell lung cancer who had received no prior systemic chemotherapy and radiotherapy. RESULTS: 1) Thirty-nine patients (limited disease: 17 patients, extensive disease 22 patients) were treated and 35 patients were evaluable for response. Overall response rate was 82.8% (complete response 28.6%, partial response 54.2%). 2) The median survival was 52 weeks for all patients and 58 weeks for limited disease and 45 weeks for extensive disease. There was no statically significant survival difference between the two patient groups. The median relapse-free survival time was 48 weeks. 3) Overall, treatment was well tolerated, with granulocytopenia being the most frequent toxicity. CONCLUSIONS: Combination chemotherapy with COPE regimen combined with radiation therapy was effective as a first line therapy for SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0029200632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029200632&partnerID=8YFLogxK

M3 - Article

C2 - 7626554

AN - SCOPUS:0029200632

VL - 10

SP - 32

EP - 37

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 1

ER -